Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Expression of glutamate carboxypeptidase II in human brain

Sácha P, Zámecník J, Barinka C, Hlouchová K, Vícha A, Mlcochová P, Hilgert I, Eckschlager T, Konvalinka J

. 2007 ; 144 (4) : 1361-1372.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc07527758

Glutamate carboxypeptidase II (GCPII) is a transmembrane glycoprotein expressed in various tissues. When expressed in the brain it cleaves the neurotransmitter N-acetylaspartylglutamate (NAAG), yielding free glutamate. In jejunum it hydrolyzes folylpoly-gamma-glutamate, thus facilitating folate absorption. The prostate form of GCPII, known as prostate specific membrane antigen (PSMA), is an established cancer marker. The NAAG-hydrolyzing activity of GCPII has been implicated in a number of pathological conditions in which glutamate is neurotoxic (e.g. amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, epilepsy, schizophrenia, and stroke). Inhibition of GCPII was shown to be neuroprotective in tissue culture and in animal models. GCPII is therefore an interesting putative therapeutic target. However, only very limited and controversial data on the expression and localization of GCPII in human brain are available. Therefore, we set out to analyze the activity and expression of GCPII in various compartments of the human brain using a radiolabeled substrate of the enzyme and the novel monoclonal antibody GCP-04, which recognizes an epitope on the extracellular portion of the enzyme and is more sensitive to GCPII than to the homologous GCPIII. We show that this antibody is more sensitive in immunoblots than the widely used antibody 7E11. By Western blot, we show that there are approximately 50-300 ng of GCPII/mg of total protein in human brain, depending on the specific area. Immunohistochemical analysis revealed that astrocytes specifically express GCPII in all parts of the brain. GCPII is enzymatically active and the level of activity follows the expression pattern. Using pure recombinant GCPII and homologous GCPIII, we conclude that GCPII is responsible for the majority of overall NAAG-hydrolyzing activity in the human brain.

Citace poskytuje Crossref.org

000      
00000naa 2200000 a 4500
001      
bmc07527758
003      
CZ-PrNML
005      
20111210144004.0
008      
090824s2007 xxu e eng||
009      
AR
024    __
$a 10.1016/j.neuroscience.2006.10.022 $2 doi
035    __
$a (PubMed)17150306
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Šácha, Pavel $7 xx0110867
245    10
$a Expression of glutamate carboxypeptidase II in human brain / $c Sácha P, Zámecník J, Barinka C, Hlouchová K, Vícha A, Mlcochová P, Hilgert I, Eckschlager T, Konvalinka J
314    __
$a Department of Biochemistry, Institute of Organic Chemistry and Biochemistry, Academy of Science of the Czech Republic, Flemingovo n.2, Prague 6, 16610 Czech Republic
520    9_
$a Glutamate carboxypeptidase II (GCPII) is a transmembrane glycoprotein expressed in various tissues. When expressed in the brain it cleaves the neurotransmitter N-acetylaspartylglutamate (NAAG), yielding free glutamate. In jejunum it hydrolyzes folylpoly-gamma-glutamate, thus facilitating folate absorption. The prostate form of GCPII, known as prostate specific membrane antigen (PSMA), is an established cancer marker. The NAAG-hydrolyzing activity of GCPII has been implicated in a number of pathological conditions in which glutamate is neurotoxic (e.g. amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, epilepsy, schizophrenia, and stroke). Inhibition of GCPII was shown to be neuroprotective in tissue culture and in animal models. GCPII is therefore an interesting putative therapeutic target. However, only very limited and controversial data on the expression and localization of GCPII in human brain are available. Therefore, we set out to analyze the activity and expression of GCPII in various compartments of the human brain using a radiolabeled substrate of the enzyme and the novel monoclonal antibody GCP-04, which recognizes an epitope on the extracellular portion of the enzyme and is more sensitive to GCPII than to the homologous GCPIII. We show that this antibody is more sensitive in immunoblots than the widely used antibody 7E11. By Western blot, we show that there are approximately 50-300 ng of GCPII/mg of total protein in human brain, depending on the specific area. Immunohistochemical analysis revealed that astrocytes specifically express GCPII in all parts of the brain. GCPII is enzymatically active and the level of activity follows the expression pattern. Using pure recombinant GCPII and homologous GCPIII, we conclude that GCPII is responsible for the majority of overall NAAG-hydrolyzing activity in the human brain.
650    _2
$a financování organizované $7 D005381
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protilátky $x imunologie $7 D000906
650    _2
$a antigeny povrchové $x analýza $x imunologie $x metabolismus $7 D000954
650    _2
$a astrocyty $x enzymologie $7 D001253
650    _2
$a western blotting $7 D015153
650    _2
$a mozek $x anatomie a histologie $x enzymologie $7 D001921
650    _2
$a dipeptidy $x metabolismus $7 D004151
650    _2
$a aktivace enzymů $x genetika $7 D004789
650    _2
$a mapování epitopu $x metody $7 D018604
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glutamátkarboxypeptidasa II $x analýza $x imunologie $x metabolismus $7 D043425
650    _2
$a kyselina glutamová $x biosyntéza $7 D018698
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $x metody $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární modely $7 D008958
650    _2
$a terciární struktura proteinů $x genetika $7 D017434
650    _2
$a radioligandová zkouška $x metody $7 D011869
650    _2
$a rekombinantní fúzní proteiny $x metabolismus $7 D011993
700    1_
$a Zámečník, Josef, $d 1974- $7 xx0037787
700    1_
$a Bařinka, Cyril $7 xx0126049
700    1_
$a Hlouchová, Klára. $7 xx0270848
700    1_
$a Vícha, Aleš, $d 1971- $7 xx0116880
700    1_
$a Mlčochová, Petra $7 xx0127960
700    1_
$a Hilgert, Ivan $7 xx0074005
700    1_
$a Eckschlager, Tomáš, $d 1956- $7 jn20000400613
700    1_
$a Konvalinka, Jan, $d 1963- $7 mzk2004208597
773    0_
$w MED00003505 $t Neuroscience $g Roč. 144, č. 4 (2007), s. 1361-1372 $x 0306-4522
910    __
$a ABA008 $b x $y 9
990    __
$a 20090824163150 $b ABA008
991    __
$a 20111103094327 $b ABA008
999    __
$a ok $b bmc $g 672788 $s 532033
BAS    __
$a 3
BMC    __
$a 2007 $b 144 $c 4 $d 1361-1372 $i 0306-4522 $m Neuroscience $x MED00003505
LZP    __
$a 2009-B4/vtme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...